To the content
2 . 2014

Pharmacoeconomic aspects of HIV therapy with the use of highly active anti-retroviral therapy fixed dose combination (emtricitabine/rilpivirine/ tenofovir)

AbstractFixed-doze combination of rilpivirine, tenofovir andemtricitabine in highly active antiretroviral therapy makes possible to decrease costs comparing to combinations of rilpivirine with fixed doze tenofovir/emtricitabine and raltegravir with fixed doze tenofovir/emtricitabine. Simultaneously fixed doze combination increases treatment compliance resulting in frequency of hospitalizations decrease and provides an opportunity to increase effectiveness of therapy in the Russian Federation.

Keywords:rilpivirine, tenofovir, emtricitabine, raltegravir, compliance, fixeddoze combination, effectiveness

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)
Journals of «GEOTAR-Media»